Shanghai No.1 Pharmacy Co Ltd

Capital Structure and Liquidity Shanghai No.1 Pharmacy Co Ltd maintains a debt-to-equity ratio of 0.21, indicating a relatively conservative capital structure. The company's current ratio of 1.59 suggests adequate short-term liquidity to cover its obligations. However, the risk assessment notes a medium liquidity risk, with net cash turning negative after subtracting total debt. ### Profitability and Returns The company's return on equity (ROE) is 4.97%, and its return on assets (ROA) is 2.86%, both below the typical thresholds for high-performing drug retailers. The net income of 57.75 million CNY and operating income of 74.77 million CNY reflect modest profitability relative to its revenue of 2.13 billion CNY. ### Segments and Geographic Exposure The company operates primarily in the domestic Chinese market, with no disclosed international revenue segments. Its business is concentrated in pharmaceutical retail and wholesale, with no material diversification into other product lines. ### Growth Trajectory The company's revenue growth is not explicitly forecasted, but the absence of significant capital expenditures (-15.93 million CNY) suggests a focus on operational efficiency rather than expansion. Analyst estimates for the last actual revenue were 934.23 million CNY, significantly lower than the reported 2.13 billion CNY, indicating potential discrepancies in forward-looking guidance. ### Risk Factors The company faces a medium liquidity risk, with net cash turning negative after subtracting total debt. The dilution risk is assessed as low, with no immediate pressure for share issuance. The absence of significant long-term debt (249.43 million CNY) reduces refinancing risk, but the company's reliance on domestic operations exposes it to regulatory and economic shifts in China. ### Recent Events No recent filings or transcripts are provided in the input data to inform recent corporate developments or strategic shifts.